Palsonify gains access and prescribers, but launch cadence remains uncertain as pipeline spending rises.
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-02-28 |
| Length | 60 minutes |
| EPS | $-1.29 |
| EPS consensus | $-1.37 |
| Revenue | $6.2M |
| Revenue consensus | $4.7M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26
Read the full Q4 FY25 earnings call transcript
All CRNX earnings ยท Back to CRNX overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.